Table 1 Demographic, clinical and serological characteristics of lcSSc patients and healthy controls
Control subjects (n = 8) | All LcSSc patients (n = 15) | ||
|---|---|---|---|
Age, median (range) years | 53 (29–70) | 62 (28–15) | |
Sex, N (%) female | 4 (50) | 12 (80) | |
Race, N (%) Caucasian | 7 (87.5) | 10 (100) | |
MRSS, median (range) | 6 (3–10) | ||
Disease duration from first non-Raynaud’s symptom, median (range) years | 14 (2–40) | ||
ANA primary pattern, N (%) patients | Homogenous | 4 (27) | |
Speckled | 2 (13) | ||
Centromere | 6 (40) | ||
Nucleolar | 1 (7) | ||
SSc-specific antibodies | Scl-70 | 4 (27) | |
RNA pol III | 0 | ||
Vasculopathy, N (%) patients | Digital ulcers | 6 (40) | |
PAH | 0 | ||
Renal crisis | 0 | ||
Interstitial lung disease, N (%) | 4 (27) | ||
Inflammatory arthritis, N (%) | 3 (20) | ||
Vascular therapies, N (%) patients | ARB | 10 (66) | |
Ca channel antagonist | 4 (27) | ||
Iloprost | 4 (27) | ||
PDE5 inhibitor | 3 (20) | ||
Immunosuppressive therapies, N (%) patients | PDN | 4 (27) | |
MMF | 3 (20) | ||
MTX | 2 (13) | ||
AZA | 1 (7) | ||
HCQ | 3 (20) | ||